A 46-year-old Chinese male nonsmoker with CML underwent allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling in 1995 after busulfancyclophosphamide conditioning. He developed moderate chronic GVHD of the mouth and skin, and cyclosporin was tapered off after 2 years. He was maintained on oral cotrimoxazole, steroid inhalations, and eye lubricants for conjunctivitis sicca, bronchiolitis obliterans, frequent episodes of pneumonia, and three episodes of herpes zoster reactivation. At 3 years after BMT, he developed a rapidly growing left superior conjunctival lesion, which showed squamous cell carcinoma (SCC) with underlying dysplasia. This was treated with excision and cryotherapy. Repeat excision and strontium 90 external beam radiotherapy (60 Gy) 4 months later resulted in symblepharon formation. After 6 months, further local relapse required cryotherapy and sclerokeratectomy at the limbus, with repair by mucous membrane graft from the lip (Figure 1 ). Residual dysplasia was treated with local mitomycin. At 5 years after the initial detection of the conjunctival tumor, impression cytology was normal. The patient had residual lower lid ectropion and with impaired visual acuity (0.02). Molecular monitoring showed no evidence of CML and tests for human immunodeficiency virus (HIV) were negative.
Second malignancies occur in up to 10% of allogeneic BMT recipients, especially those with GVHD and conditioned with total body irradiation. Common cancers include SCC of the skin and mouth as well as liver cancer, which may be related to GVHD in these organs.
1 Although GVHD-related conjunctivitis sicca is common in BMT recipients, dry eye per se may not be a risk factor for a secondary malignancy, since patients with Sjogren-related 2 Although post-BMT conjunctival SCC is hitherto unreported, it is a common opportunistic cancer in young African HIV carriers. 3 Possible risk factors included human papillomavirus (HPV) reactivation, ultraviolet exposure and low CD4 counts. In solid organ recipients, four cases of conjunctival SCC have been reported (Table 1) , and investigations for HPV were negative in two cases. [4] [5] [6] All cases were on life-long immunosuppression and the latency to SCC ranged from 3 to 13 years. In our case, despite the recovery of lymphocyte counts, discontinuation of cyclosporin A and good immunological control of the CML clone, the occurrence of repeated zoster reactivation pointed to some degree of impaired T cell function. Conjunctival SCC in transplant recipients is mainly a localized disease with good prognosis. However, it is notable that local recurrences and repeat excisions occurred in all reported cases (Table 1) . Cryotherapy, radiotherapy, and mitomycin may all reduce the relapse risk. After extensive resection, corneal reconstruction may also be problem, especially in BMT recipients with cGVHD, who suffer from bilateral dry eyes and ocular limbal stem cell deficiency to replenish the cornea. Corneal grafts have not been reported in BMT recipients. Although an autologous mucosal graft was used in this case, it is possible that immunological tolerance of other graft tissues may be increased in allogeneic BMT recipients. 
